KeraNetics, LLC is developing an innovative, injectable/flowable biomaterial for delivery of bone morphogenetic protein (BMP) or other growth factors, overcoming the current limitations of pure delivery of growth factors and addressing a significant unmet medical need for repair of craniofacial injuries resulting from traumatic battlefield injuries for which current treatments cannot address. Craniofacial injuries impact beyond just the apparent disfigurement to psychological well-being, causing the individual to become detached and unproductive member of society. The company has an established partnership with Pfizer, who owns the BMP technology for sale; thus, development of this technology for sales is very likely given a Fortune 500 company's investment and partnership to help advance the technology development from Phase II to successful commercialization. BMP and BMP related sales currently is worth $865 million USD. Novel delivery systems are needed to overcome the complications associated with pure protein delivery. Hence, keratin-based biomaterials could addressed this and the cost production of this is very low. In addition, controlled delivery could allow for smaller doses of BMP, thereby further decreasing the treatment cost. The company has been a true government partner in addressing and tailoring to the needs of the government and makes every effort in demonstrating its technology feasibilities, beyond what is called for in the SBIR deliverables. Hence, this company is highly recommended for consideration of the Tibbetts Award.